Clinical Trials

During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.

As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio Ascierto, MD, of the Istituto Nazionale dei Tumori IRCCS in Naples, Italy, at the 2024 ASCO Annual Meeting.

The triplet combination of nivolumab, relatlimab, and ipilimumab offered promising response rates and survival outcomes in patients with untreated advanced melanoma, according to preliminary data from the nonrandomized phase 1/2 RELATIVITY-048 trial (Abstract 9504). Although the results require confirmation in larger randomized trials, the 4-year overall survival (OS) rate seen with the triplet regimen compares favorably with other nivolumab-based combinations in this setting.

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.